Clinical Trials Directory

Trials / Unknown

UnknownNCT00094913

PET Changes in Alzheimer's Disease (AD)

Clinical Correlates of Longitudinal PET Changes in Alzheimer's Disease (AD)

Status
Unknown
Phase
Study type
Observational
Enrollment
105 (estimated)
Sponsor
National Institute on Aging (NIA) · NIH
Sex
All
Age
20 Years – 90 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to identify the earliest predictors of memory and brain deterioration in pre-clinical Alzheimer's disease using positron emission tomography (PET) to monitor brain glucose metabolism.

Detailed description

Previous studies indicate that the brain's glucose metabolism rate potentially may be an early indicator of damage to particular regions of the brain caused by AD, including loss of neurons, synapses, and other changes. Many of these changes are reported among patients with mild cognitive impairment (MCI), a group known to be at increased risk for AD. The overall goal of this study is to use FDG-PET (2-\[(18)F\]fluoro-2-deoxy-d-glucose/positron-emission tomography) to determine whether metabolic abnormalities in the hippocampus predict memory and brain deterioration in middle age, and to identify the brain glucose metabolism predictors of future MCI. Participants in the study will be grouped into 3 main groups of 35 each, including young individuals (20-40 years of age), 41-90 year-old normal, and MCI individuals with or without risk for memory decline. Participants will undergo baseline and 36-month follow-up exams to include comprehensive medical, neurologic, and psychiatric evalutions; lumbar puncture; a resting FDG-PET; an MRI scan; and a neuropsychological battery. A brief medical exam, full neuropsychological battery, and MRI scan will be administered at 18 months. Two subgroups (groups 4 and 5) of 15 each will be created from groups 1 and 2 at 18 months to participate in the evaluation of memory performance under acute hyperglycemia and saline challenges and effects on hippocampal formation and glucose metabolism.

Conditions

Timeline

Start date
2004-05-01
Completion
2005-04-01
First posted
2004-10-29
Last updated
2009-05-27

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00094913. Inclusion in this directory is not an endorsement.